Alembic Pharmaceuticals Limited Share Price

Equities

APLLTD

INE901L01018

Pharmaceuticals

Delayed NSE India S.E. 12:32:20 18/05/2024 pm IST 5-day change 1st Jan Change
967.8 INR +0.82% Intraday chart for Alembic Pharmaceuticals Limited -0.80% +27.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 6.23TCr 75Cr Sales 2025 * 6.99TCr 84Cr Capitalization 19TCr 228.55Cr
Net income 2024 615.8Cr 7.4Cr Net income 2025 * 697.8Cr 8.38Cr EV / Sales 2024 3.11 x
Net Debt 2024 * 261.68Cr 3.14Cr Net cash position 2025 * 84Cr 1Cr EV / Sales 2025 * 2.71 x
P/E ratio 2024
31.4 x
P/E ratio 2025 *
27.2 x
Employees 14,593
Yield 2024 *
0.92%
Yield 2025 *
0.9%
Free-Float 29.28%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Alembic Pharmaceuticals Limited, Q4 2024 Earnings Call, May 09, 2024
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q4 MT
India's Alembic Pharma posts higher Q4 profit on strong N.America sales RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Alembic Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Alembic Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24 CI
Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals CI
Alembic Pharmaceuticals Limited Receives an Order from the Office of Deputy Commissioner, DGSTO-02, Bengaluru, Karnataka CI
Alembic Pharmaceuticals Limited Receives Order from the Office of Deputy Commissioner (ST), Guwahati, Assam CI
Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3% MT
Alembic Pharmaceuticals Limited Received 3 Assessment Orders from the Office of Assistant Commissioner (ST), Andhra Pradesh CI
Alembic Pharmaceuticals Appoints Manish Kejriwal as Independent Director CI
Alembic Pharmaceuticals Gets US FDA Tentative Nod for Generic Breast Cancer Treatment MT
Alembic Pharmaceuticals Limited Receives One US Food & Drug Administration Product Approval CI
Alembic Pharmaceuticals Limited Announces Board Cessations CI
More news
1 day+0.82%
1 week-0.80%
Current month-3.19%
1 month+3.13%
3 months-3.63%
6 months+31.26%
Current year+27.44%
More quotes
1 week
951.00
Extreme 951
989.95
1 month
933.50
Extreme 933.5
1 050.80
Current year
773.40
Extreme 773.4
1 094.00
1 year
542.40
Extreme 542.4
1 094.00
3 years
462.30
Extreme 462.3
1 094.00
5 years
434.80
Extreme 434.8
1 145.00
10 years
237.00
Extreme 237
1 145.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 76 01/83/01
Director of Finance/CFO 64 18/03/18
Compliance Officer - 01/23/01
Members of the board TitleAgeSince
Chief Executive Officer 76 01/83/01
Director of Finance/CFO 64 18/03/18
Director/Board Member 56 04/15/04
More insiders
Date Price Change Volume
18/24/18 967.8 +0.82% 4,260
17/24/17 959.9 -1.04% 43,212
16/24/16 970 +0.19% 63,359
15/24/15 968.2 +0.31% 82,621
14/24/14 965.2 +1.25% 86,264

Delayed Quote NSE India S.E., May 18, 2024 at 12:32 pm IST

More quotes
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
967.8 INR
Average target price
980.3 INR
Spread / Average Target
+1.30%
Consensus
  1. Stock Market
  2. Equities
  3. APLLTD Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW